Apixaban in low-weight patients with cancer-associated thrombosis: A cross sectional study of drug levels.

Verónica Bravo VillaJob RomeroEunice Rojas-ZaldivarMartha CervantesMaría Del Rosario Villa-MárquezPatricia BazGabriela Cesarman-Maus

Published in: Research and practice in thrombosis and haemostasis (2021)

This study supports the rationale for studying weight-based adjustments in apixaban dosing in prospective studies evaluating safety and efficacy of dose reduction in low-weight patients with cancer.

Keyphrases

physical activity
body mass index
weight loss
weight gain
venous thromboembolism
atrial fibrillation
body weight
pulmonary embolism
clinical trial
risk factors
emergency department
drug induced
electronic health record